Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

• Published in: Clinical cancer research 2020-11, Vol.26 (22), p.6039-6050
• Main Authors: Marusak, Charles, Thakur, Varsha, Li, Yuan, Freitas, Juliano T, Zmina, Patrick M, Thakur, Vijay S, Chang, Mayland, Gao, Ming, Tan, Jiufeng, Xiao, Min, Lu, Yiling, Mills, Gordon B, Flaherty, Keith, Frederick, Dennie T, Miao, Benchun, Sullivan, Ryan J, Moll, Tabea, Boland, Genevieve M, Herlyn, Meenhard, Zhang, Gao, Bedogni, Barbara
• Format: Article
• Language: English
• Subjects: Animals; Arginine - analogs & derivatives; Arginine - pharmacology; Cell Line, Tumor; Drug Resistance, Neoplasm - drug effects; Focal Adhesion Kinase 1 - genetics; Gene Expression Regulation, Neoplastic - drug effects; Heterografts; Humans; Integrin beta1 - genetics; Matrix Metalloproteinase 14 - genetics; Melanoma - drug therapy; Melanoma - genetics; Melanoma - pathology; Mice; Protein Kinase Inhibitors - pharmacology; Proto-Oncogene Proteins B-raf - antagonists & inhibitors; Proto-Oncogene Proteins B-raf - genetics; Signal Transduction - drug effects; Sulfones - pharmacology; Transforming Growth Factor beta - genetics; Vemurafenib - pharmacology
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.ccr-19-2773

The extracellular matrix (ECM) is an intriguing, yet understudied component of therapy resistance. Here, we investigated the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant melanoma to BRAF inhibitor (BRAFi) therapy. Publicly available RNA-sequencing data and reverse phase protein array were used to determine the relevance of MT1-MMP upregulation in BRAFi-resistant melanoma in patients, patient-derived xenografts, and cell line-derived tumors. Short hairpin RNA (shRNA)-mediated knockdown of MT1-MMP, inhibition via the selective MT1-MMP/MMP2 inhibitor, ND322, or overexpression of MT1-MMP was used to assess the role of MT1-MMP in mediating resistance to BRAFi. MT1-MMP was consistently upregulated in posttreatment tumor samples derived from patients upon disease progression and in melanoma xenografts and cell lines that acquired resistance to BRAFi. shRNA- or ND322-mediated inhibition of MT1-MMP synergized with BRAFi leading to resensitization of resistant cells and tumors to BRAFi. The resistant phenotype depends on the ability of cells to cleave the ECM. Resistant cells seeded in MT1-MMP uncleavable matrixes were resensitized to BRAFi similarly to MT1-MMP inhibition. This is due to the inability of cells to activate integrinβ1 (ITGB1)/FAK signaling, as restoration of ITGB1 activity is sufficient to maintain resistance to BRAFi in the context of MT1-MMP inhibition. Finally, the increase in MT1-MMP in BRAFi-resistant cells is TGFβ dependent, as inhibition of TGFβ receptors I/II dampens MT1-MMP overexpression and restores sensitivity to BRAF inhibition. BRAF inhibition results in a selective pressure toward higher expression of MT1-MMP. MT1-MMP is pivotal to an ECM-based signaling pathway that confers resistance to BRAFi therapy.